Bulis Veronica Sanchez
Known title: VP, Corporate ControllerCIK: 0002095702
Associated companies
Transaction History
| LYEL | ▼ Sell | Open Market | 621 | $9K | 8/10/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 217 | $4K | 5/11/2026 | View on chart |
| LYEL | ▲ Buy | Grant | 8,750 | $0 | 2/10/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 254 | $6K | 2/10/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 936 | $30K | 12/30/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 1,136 | $44K | 12/24/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 239 | $4K | 11/10/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks
The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.